APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hemophilia A Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hemophilia A Drug Market Outlook and Growth Opportunities 2026

22 December 2025192 pages

Choose your research edition.

Industry ResearchHemophilia A Drug Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Hemophilia A Drug Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Hemophilia A Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hemophilia A Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Hemophilia A Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Hemophilia A Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hemophilia A Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hemophilia A Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hemophilia A Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hemophilia A Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hemophilia A Drug market include Bayer AG, mAbxience SA, LFB SA, Immusoft Corp, Idogen AB, Green Cross Corp, Expression Therapeutics LLC, EpiVax Inc and Dimension Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hemophilia A Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hemophilia A Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hemophilia A Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hemophilia A Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Hemophilia A Drug Segment by Company

Bayer AG

mAbxience SA

LFB SA

Immusoft Corp

Idogen AB

Green Cross Corp

Expression Therapeutics LLC

EpiVax Inc

Dimension Therapeutics Inc

DBV Technologies SA

CSL Ltd

Chugai Pharmaceutical Co Ltd

Catalyst Biosciences Inc

Bioverativ Inc

BioMarin Pharmaceutical Inc

Hemophilia A Drug Segment by Type

ATXF-8117

BAY-1093884

BIVV-001

BS-027125

Concizumab

CSL-689

Others

Hemophilia A Drug Segment by Application

Clinic

Hospital

ASCs

Hemophilia A Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hemophilia A Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Hemophilia A Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hemophilia A Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Hemophilia A Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia A Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hemophilia A Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia A Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hemophilia A Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hemophilia A Drug industry.

Chapter 3: Detailed analysis of Hemophilia A Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Hemophilia A Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Hemophilia A Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hemophilia A Drug Industry Trends Table 2. Hemophilia A Drug Industry Drivers Table 3. Hemophilia A Drug Industry Opportunities and Challenges Table 4. Hemophilia A Drug Industry Restraints Table 5. Global Hemophilia A Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hemophilia A Drug Revenue Share by Company (2021-2026) Table 7. Global Hemophilia A Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global Hemophilia A Drug Sales Volume Share by Company (2021-2026) Table 9. Global Hemophilia A Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global Hemophilia A Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Hemophilia A Drug Key Company Manufacturing Base & Headquarters Table 12. Global Hemophilia A Drug Company, Product Type & Application Table 13. Global Hemophilia A Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Hemophilia A Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of ATXF-8117 Table 18. Significant Companies of BAY-1093884 Table 19. Significant Companies of BIVV-001 Table 20. Significant Companies of BS-027125 Table 21. Significant Companies of Concizumab Table 22. Significant Companies of CSL-689 Table 23. Significant Companies of Others Table 24. Global Hemophilia A Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Hemophilia A Drug Sales Volume by Type (2021-2026) & (k units) Table 26. Global Hemophilia A Drug Sales Volume by Type (2027-2032) & (k units) Table 27. Global Hemophilia A Drug Sales Volume Share by Type (2021-2026) Table 28. Global Hemophilia A Drug Sales Volume Share by Type (2027-2032) Table 29. Global Hemophilia A Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Hemophilia A Drug Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global Hemophilia A Drug Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global Hemophilia A Drug Sales Value Share by Type (2021-2026) Table 33. Global Hemophilia A Drug Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Clinic Table 35. Significant Companies of Hospital Table 36. Significant Companies of ASCs Table 37. Global Hemophilia A Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Hemophilia A Drug Sales Volume by Application (2021-2026) & (k units) Table 39. Global Hemophilia A Drug Sales Volume by Application (2027-2032) & (k units) Table 40. Global Hemophilia A Drug Sales Volume Share by Application (2021-2026) Table 41. Global Hemophilia A Drug Sales Volume Share by Application (2027-2032) Table 42. Global Hemophilia A Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Hemophilia A Drug Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Hemophilia A Drug Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Hemophilia A Drug Sales Value Share by Application (2021-2026) Table 46. Global Hemophilia A Drug Sales Value Share by Application (2027-2032) Table 47. Global Hemophilia A Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 48. Global Hemophilia A Drug Sales by Region (2021-2026) & (k units) Table 49. Global Hemophilia A Drug Sales Market Share by Region (2021-2026) Table 50. Global Hemophilia A Drug Sales by Region (2027-2032) & (k units) Table 51. Global Hemophilia A Drug Sales Market Share by Region (2027-2032) Table 52. Global Hemophilia A Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Hemophilia A Drug Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Hemophilia A Drug Sales Value Share by Region (2021-2026) Table 55. Global Hemophilia A Drug Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Hemophilia A Drug Sales Value Share by Region (2027-2032) Table 57. Global Hemophilia A Drug Market Average Price (US$/unit) by Region (2021-2026) Table 58. Global Hemophilia A Drug Market Average Price (US$/unit) by Region (2027-2032) Table 59. Global Hemophilia A Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 60. Global Hemophilia A Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Hemophilia A Drug Sales by Country (2021-2026) & (k units) Table 62. Global Hemophilia A Drug Sales Market Share by Country (2021-2026) Table 63. Global Hemophilia A Drug Sales by Country (2027-2032) & (k units) Table 64. Global Hemophilia A Drug Sales Market Share by Country (2027-2032) Table 65. Global Hemophilia A Drug Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Hemophilia A Drug Sales Value Market Share by Country (2021-2026) Table 67. Global Hemophilia A Drug Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Hemophilia A Drug Sales Value Market Share by Country (2027-2032) Table 69. Bayer AG Company Information Table 70. Bayer AG Business Overview Table 71. Bayer AG Hemophilia A Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Bayer AG Hemophilia A Drug Product Portfolio Table 73. Bayer AG Recent Development Table 74. mAbxience SA Company Information Table 75. mAbxience SA Business Overview Table 76. mAbxience SA Hemophilia A Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. mAbxience SA Hemophilia A Drug Product Portfolio Table 78. mAbxience SA Recent Development Table 79. LFB SA Company Information Table 80. LFB SA Business Overview Table 81. LFB SA Hemophilia A Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. LFB SA Hemophilia A Drug Product Portfolio Table 83. LFB SA Recent Development Table 84. Immusoft Corp Company Information Table 85. Immusoft Corp Business Overview Table 86. Immusoft Corp Hemophilia A Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Immusoft Corp Hemophilia A Drug Product Portfolio Table 88. Immusoft Corp Recent Development Table 89. Idogen AB Company Information Table 90. Idogen AB Business Overview Table 91. Idogen AB Hemophilia A Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Idogen AB Hemophilia A Drug Product Portfolio Table 93. Idogen AB Recent Development Table 94. Green Cross Corp Company Information Table 95. Green Cross Corp Business Overview Table 96. Green Cross Corp Hemophilia A Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Green Cross Corp Hemophilia A Drug Product Portfolio Table 98. Green Cross Corp Recent Development Table 99. Expression Therapeutics LLC Company Information Table 100. Expression Therapeutics LLC Business Overview Table 101. Expression Therapeutics LLC Hemophilia A Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Expression Therapeutics LLC Hemophilia A Drug Product Portfolio Table 103. Expression Therapeutics LLC Recent Development Table 104. EpiVax Inc Company Information Table 105. EpiVax Inc Business Overview Table 106. EpiVax Inc Hemophilia A Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. EpiVax Inc Hemophilia A Drug Product Portfolio Table 108. EpiVax Inc Recent Development Table 109. Dimension Therapeutics Inc Company Information Table 110. Dimension Therapeutics Inc Business Overview Table 111. Dimension Therapeutics Inc Hemophilia A Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Dimension Therapeutics Inc Hemophilia A Drug Product Portfolio Table 113. Dimension Therapeutics Inc Recent Development Table 114. DBV Technologies SA Company Information Table 115. DBV Technologies SA Business Overview Table 116. DBV Technologies SA Hemophilia A Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. DBV Technologies SA Hemophilia A Drug Product Portfolio Table 118. DBV Technologies SA Recent Development Table 119. CSL Ltd Company Information Table 120. CSL Ltd Business Overview Table 121. CSL Ltd Hemophilia A Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. CSL Ltd Hemophilia A Drug Product Portfolio Table 123. CSL Ltd Recent Development Table 124. Chugai Pharmaceutical Co Ltd Company Information Table 125. Chugai Pharmaceutical Co Ltd Business Overview Table 126. Chugai Pharmaceutical Co Ltd Hemophilia A Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Chugai Pharmaceutical Co Ltd Hemophilia A Drug Product Portfolio Table 128. Chugai Pharmaceutical Co Ltd Recent Development Table 129. Catalyst Biosciences Inc Company Information Table 130. Catalyst Biosciences Inc Business Overview Table 131. Catalyst Biosciences Inc Hemophilia A Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Catalyst Biosciences Inc Hemophilia A Drug Product Portfolio Table 133. Catalyst Biosciences Inc Recent Development Table 134. Bioverativ Inc Company Information Table 135. Bioverativ Inc Business Overview Table 136. Bioverativ Inc Hemophilia A Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Bioverativ Inc Hemophilia A Drug Product Portfolio Table 138. Bioverativ Inc Recent Development Table 139. BioMarin Pharmaceutical Inc Company Information Table 140. BioMarin Pharmaceutical Inc Business Overview Table 141. BioMarin Pharmaceutical Inc Hemophilia A Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. BioMarin Pharmaceutical Inc Hemophilia A Drug Product Portfolio Table 143. BioMarin Pharmaceutical Inc Recent Development Table 144. Key Raw Materials Table 145. Raw Materials Key Suppliers Table 146. Hemophilia A Drug Distributors List Table 147. Hemophilia A Drug Customers List Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Hemophilia A Drug Product Image Figure 2. Global Hemophilia A Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hemophilia A Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Hemophilia A Drug Sales (2021-2032) & (k units) Figure 5. Global Hemophilia A Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Hemophilia A Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. ATXF-8117 Image Figure 10. BAY-1093884 Image Figure 11. BIVV-001 Image Figure 12. BS-027125 Image Figure 13. Concizumab Image Figure 14. CSL-689 Image Figure 15. Others Image Figure 16. Global Hemophilia A Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Hemophilia A Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global Hemophilia A Drug Sales Volume Share by Type (2021-2032) Figure 19. Global Hemophilia A Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Hemophilia A Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Hemophilia A Drug Sales Value Share by Type (2021-2032) Figure 22. Clinic Image Figure 23. Hospital Image Figure 24. ASCs Image Figure 25. Global Hemophilia A Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Hemophilia A Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Hemophilia A Drug Sales Volume Share by Application (2021-2032) Figure 28. Global Hemophilia A Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Hemophilia A Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Hemophilia A Drug Sales Value Share by Application (2021-2032) Figure 31. Global Hemophilia A Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 32. Global Hemophilia A Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Hemophilia A Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Hemophilia A Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Hemophilia A Drug Sales Value (2021-2032) & (US$ Million) Figure 36. North America Hemophilia A Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Hemophilia A Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Hemophilia A Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Hemophilia A Drug Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Hemophilia A Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Hemophilia A Drug Sales Value (2021-2032) & (US$ Million) Figure 42. South America Hemophilia A Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Hemophilia A Drug Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Hemophilia A Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Hemophilia A Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Hemophilia A Drug Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Hemophilia A Drug Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • ATXF-8117
  • BAY-1093884
  • BIVV-001
  • BS-027125
  • Concizumab
  • CSL-689
  • Others
Applications
  • Clinic
  • Hospital
  • ASCs
Companies covered
  • Bayer AG
  • mAbxience SA
  • LFB SA
  • Immusoft Corp
  • Idogen AB
  • Green Cross Corp
  • Expression Therapeutics LLC
  • EpiVax Inc
  • Dimension Therapeutics Inc
  • DBV Technologies SA
  • CSL Ltd
  • Chugai Pharmaceutical Co Ltd
  • Catalyst Biosciences Inc
  • Bioverativ Inc
  • BioMarin Pharmaceutical Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hemophilia A Drug Sales Value (2021-2032)
  4. 1.2.2 Global Hemophilia A Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Hemophilia A Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Hemophilia A Drug Market Dynamics
  1. 2.1 Hemophilia A Drug Industry Trends
  2. 2.2 Hemophilia A Drug Industry Drivers
  3. 2.3 Hemophilia A Drug Industry Opportunities and Challenges
  4. 2.4 Hemophilia A Drug Industry Restraints
3 Hemophilia A Drug Market by Company
  1. 3.1 Global Hemophilia A Drug Company Revenue Ranking in 2025
  2. 3.2 Global Hemophilia A Drug Revenue by Company (2021-2026)
  3. 3.3 Global Hemophilia A Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Hemophilia A Drug Average Price by Company (2021-2026)
  5. 3.5 Global Hemophilia A Drug Company Ranking (2024-2026)
  6. 3.6 Global Hemophilia A Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Hemophilia A Drug Company Product Type and Application
  8. 3.8 Global Hemophilia A Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Hemophilia A Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Hemophilia A Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Hemophilia A Drug Market by Type
  1. 4.1 Hemophilia A Drug Type Introduction
  2. 4.1.1 ATXF-8117
  3. 4.1.2 BAY-1093884
  4. 4.1.3 BIVV-001
  5. 4.1.4 BS-027125
  6. 4.1.5 Concizumab
  7. 4.1.6 CSL-689
  8. 4.1.7 Others
  9. 4.2 Global Hemophilia A Drug Sales Volume by Type
  10. 4.2.1 Global Hemophilia A Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Hemophilia A Drug Sales Volume by Type (2021-2032)
  12. 4.2.3 Global Hemophilia A Drug Sales Volume Share by Type (2021-2032)
  13. 4.3 Global Hemophilia A Drug Sales Value by Type
  14. 4.3.1 Global Hemophilia A Drug Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Hemophilia A Drug Sales Value by Type (2021-2032)
  16. 4.3.3 Global Hemophilia A Drug Sales Value Share by Type (2021-2032)
5 Hemophilia A Drug Market by Application
  1. 5.1 Hemophilia A Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 ASCs
  5. 5.2 Global Hemophilia A Drug Sales Volume by Application
  6. 5.2.1 Global Hemophilia A Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hemophilia A Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Hemophilia A Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Hemophilia A Drug Sales Value by Application
  10. 5.3.1 Global Hemophilia A Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hemophilia A Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Hemophilia A Drug Sales Value Share by Application (2021-2032)
6 Hemophilia A Drug Regional Sales and Value Analysis
  1. 6.1 Global Hemophilia A Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hemophilia A Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Hemophilia A Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Hemophilia A Drug Sales by Region (2027-2032)
  5. 6.3 Global Hemophilia A Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Hemophilia A Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Hemophilia A Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Hemophilia A Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Hemophilia A Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Hemophilia A Drug Sales Value (2021-2032)
  12. 6.6.2 North America Hemophilia A Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Hemophilia A Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Hemophilia A Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Hemophilia A Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Hemophilia A Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Hemophilia A Drug Sales Value (2021-2032)
  21. 6.9.2 South America Hemophilia A Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Hemophilia A Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Hemophilia A Drug Sales Value Share by Country, 2025 VS 2032
7 Hemophilia A Drug Country-level Sales and Value Analysis
  1. 7.1 Global Hemophilia A Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hemophilia A Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Hemophilia A Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Hemophilia A Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Hemophilia A Drug Sales by Country (2027-2032)
  6. 7.4 Global Hemophilia A Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Hemophilia A Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Hemophilia A Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Hemophilia A Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Hemophilia A Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Hemophilia A Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bayer AG
  2. 8.1.1 Bayer AG Company Information
  3. 8.1.2 Bayer AG Business Overview
  4. 8.1.3 Bayer AG Hemophilia A Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bayer AG Hemophilia A Drug Product Portfolio
  6. 8.1.5 Bayer AG Recent Developments
  7. 8.2 mAbxience SA
  8. 8.2.1 mAbxience SA Company Information
  9. 8.2.2 mAbxience SA Business Overview
  10. 8.2.3 mAbxience SA Hemophilia A Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 mAbxience SA Hemophilia A Drug Product Portfolio
  12. 8.2.5 mAbxience SA Recent Developments
  13. 8.3 LFB SA
  14. 8.3.1 LFB SA Company Information
  15. 8.3.2 LFB SA Business Overview
  16. 8.3.3 LFB SA Hemophilia A Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 LFB SA Hemophilia A Drug Product Portfolio
  18. 8.3.5 LFB SA Recent Developments
  19. 8.4 Immusoft Corp
  20. 8.4.1 Immusoft Corp Company Information
  21. 8.4.2 Immusoft Corp Business Overview
  22. 8.4.3 Immusoft Corp Hemophilia A Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Immusoft Corp Hemophilia A Drug Product Portfolio
  24. 8.4.5 Immusoft Corp Recent Developments
  25. 8.5 Idogen AB
  26. 8.5.1 Idogen AB Company Information
  27. 8.5.2 Idogen AB Business Overview
  28. 8.5.3 Idogen AB Hemophilia A Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Idogen AB Hemophilia A Drug Product Portfolio
  30. 8.5.5 Idogen AB Recent Developments
  31. 8.6 Green Cross Corp
  32. 8.6.1 Green Cross Corp Company Information
  33. 8.6.2 Green Cross Corp Business Overview
  34. 8.6.3 Green Cross Corp Hemophilia A Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Green Cross Corp Hemophilia A Drug Product Portfolio
  36. 8.6.5 Green Cross Corp Recent Developments
  37. 8.7 Expression Therapeutics LLC
  38. 8.7.1 Expression Therapeutics LLC Company Information
  39. 8.7.2 Expression Therapeutics LLC Business Overview
  40. 8.7.3 Expression Therapeutics LLC Hemophilia A Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Expression Therapeutics LLC Hemophilia A Drug Product Portfolio
  42. 8.7.5 Expression Therapeutics LLC Recent Developments
  43. 8.8 EpiVax Inc
  44. 8.8.1 EpiVax Inc Company Information
  45. 8.8.2 EpiVax Inc Business Overview
  46. 8.8.3 EpiVax Inc Hemophilia A Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 EpiVax Inc Hemophilia A Drug Product Portfolio
  48. 8.8.5 EpiVax Inc Recent Developments
  49. 8.9 Dimension Therapeutics Inc
  50. 8.9.1 Dimension Therapeutics Inc Company Information
  51. 8.9.2 Dimension Therapeutics Inc Business Overview
  52. 8.9.3 Dimension Therapeutics Inc Hemophilia A Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Dimension Therapeutics Inc Hemophilia A Drug Product Portfolio
  54. 8.9.5 Dimension Therapeutics Inc Recent Developments
  55. 8.10 DBV Technologies SA
  56. 8.10.1 DBV Technologies SA Company Information
  57. 8.10.2 DBV Technologies SA Business Overview
  58. 8.10.3 DBV Technologies SA Hemophilia A Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 DBV Technologies SA Hemophilia A Drug Product Portfolio
  60. 8.10.5 DBV Technologies SA Recent Developments
  61. 8.11 CSL Ltd
  62. 8.11.1 CSL Ltd Company Information
  63. 8.11.2 CSL Ltd Business Overview
  64. 8.11.3 CSL Ltd Hemophilia A Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 CSL Ltd Hemophilia A Drug Product Portfolio
  66. 8.11.5 CSL Ltd Recent Developments
  67. 8.12 Chugai Pharmaceutical Co Ltd
  68. 8.12.1 Chugai Pharmaceutical Co Ltd Company Information
  69. 8.12.2 Chugai Pharmaceutical Co Ltd Business Overview
  70. 8.12.3 Chugai Pharmaceutical Co Ltd Hemophilia A Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Chugai Pharmaceutical Co Ltd Hemophilia A Drug Product Portfolio
  72. 8.12.5 Chugai Pharmaceutical Co Ltd Recent Developments
  73. 8.13 Catalyst Biosciences Inc
  74. 8.13.1 Catalyst Biosciences Inc Company Information
  75. 8.13.2 Catalyst Biosciences Inc Business Overview
  76. 8.13.3 Catalyst Biosciences Inc Hemophilia A Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Catalyst Biosciences Inc Hemophilia A Drug Product Portfolio
  78. 8.13.5 Catalyst Biosciences Inc Recent Developments
  79. 8.14 Bioverativ Inc
  80. 8.14.1 Bioverativ Inc Company Information
  81. 8.14.2 Bioverativ Inc Business Overview
  82. 8.14.3 Bioverativ Inc Hemophilia A Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Bioverativ Inc Hemophilia A Drug Product Portfolio
  84. 8.14.5 Bioverativ Inc Recent Developments
  85. 8.15 BioMarin Pharmaceutical Inc
  86. 8.15.1 BioMarin Pharmaceutical Inc Company Information
  87. 8.15.2 BioMarin Pharmaceutical Inc Business Overview
  88. 8.15.3 BioMarin Pharmaceutical Inc Hemophilia A Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 BioMarin Pharmaceutical Inc Hemophilia A Drug Product Portfolio
  90. 8.15.5 BioMarin Pharmaceutical Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hemophilia A Drug Value Chain Analysis
  2. 9.1.1 Hemophilia A Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hemophilia A Drug Sales Mode & Process
  6. 9.2 Hemophilia A Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hemophilia A Drug Distributors
  9. 9.2.3 Hemophilia A Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst